Abstract:BackgroundPatients with hepatocellular carcinoma (HCC) have poor prognosis, especially in advanced stages. Targeted therapy is the main treatment for advanced HCC patients, but the optimal targets for HCC remain poorly understood. The main purpose of this study was to identify potential novel prognostic markers and therapeutic targets.MethodsFirstly, differentially expressed genes (DEGs) in HCC were identified from the Gene Expression Omnibus (GEO) database. The expression, significance in prognosis, and potential mechanisms of DEGs were analyzed using GEPIA, TIMER, HPA, Kaplan Meier Plotter, CBioPortal, miRWalk, TargetScan, and ENCORI databases. Immunohistochemical staining was used to determine the protein expression levels of potential candidate genes.ResultsThe mRNA levels of MND1, STXBP6, and CLGN were significantly increased in HCC (p< 0.01). HCC patients with elevated CLGN mRNA levels had poorer overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and disease-specific survival (DSS) (p < 0.05). Higher MND1 mRNA levels significantly correlated with poorer DFS in HCC patients (p< 0.05). However, there was no significant correlation between STXBP6 expression and prognosis of HCC (p> 0.05). Further analysis revealed that patients with elevated CLGN mRNA expression in advanced pathology stages had poorer prognosis (p< 0.01). In addition, CLGN protein levels were elevated in HCC compared to their levels in normal tissues. The mRNA levels of CLGN had no significant correlation with the abundance of six common tumor infiltrating lymphocytes in HCC (COR < 0.5). Moreover, the mutation rate of CLGN was less than 1% in HCC patients (10/1089). Finally, the expression level of hsa-miR-194-3p in HCC was significantly lower than that in normal tissues (p < 0.05), and prognosis of HCC with low expression of hsa-miR-194 was poor (p < 0.05).ConclusionThe upregulation of CLGN in HCC is significantly associated with poor patient prognosis, especially in the advanced stages, and may be regulated by hsa-miR-194-3p. These findings suggest that CLGN may be closely related to the progression of HCC, and is a potential therapeutic target and prognostic indicator for patients with advanced HCC.

Prognostic Values of Long Non-Coding RNA MIR22HG for Patients with Hepatocellular Carcinoma after Hepatectomy.

Lncrna MIR22HG-Derived Mir-22-5p Enhances the Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Through the Inhibition of HDAC2 Activity

MIR22HG As A Tumor Suppressive lncRNA In HCC: A Comprehensive Analysis Integrating RT-qPCR, mRNA-Seq, And Microarrays.

LncRNA MIR22HG Inhibits Growth, Migration and Invasion Through Regulating the Mir‐10a‐5p/ncor2 Axis in Hepatocellular Carcinoma Cells

Correlation Between Expression Levels of Lncrna UCA1 and Mir-18A with Prognosis of Hepatocellular Cancer.

Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers

Expression Levels of Lncrnas Are Prognostic for Hepatocellular Carcinoma Overall Survival.

Expression of Serum Micrornas (Mir-222, Mir-181, Mir-216) in Human Hepatocellular Carcinoma and Its Clinical Significance

Long non‐coding RNA MIR31HG as a prognostic predictor for malignant cancers: A meta‐ and bioinformatics analysis

Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling Via Oncogenes YBX1, MET, and P21 in Lung Cancer.

High Mir-454-3p Expression Predicts Poor Prognosis in Hepatocellular Carcinoma

The Predictive Value of Lncrna MIR31HG Expression on Clinical Outcomes in Patients with Solid Malignant Tumors

Long Noncoding RNA Mir503hg, a Prognostic Indicator, Inhibits Tumor Metastasis by Regulating the HNRNPA2B1/NF-κB Pathway in Hepatocellular Carcinoma.

Genome-Wide Analysis of Prognostic Lncrnas, Mirnas, and Mrnas Forming a Competing Endogenous RNA Network in Hepatocellular Carcinoma

Effects of Mirna-140 on the Growth and Clinical Prognosis of SMMC-7721 Hepatocellular Carcinoma Cell Line

Long noncoding RNA MIR22HG is down-regulated in prostate cancer

Expression of miR-22 in Serum of Hepatocellular Carcinoma Patients after Liver Transplantation and its Clinical Significance

The Mrna-Mirna-lncrna Regulatory Network and Factors Associated with Prognosis Prediction of Hepatocellular Carcinoma

Mir-17-5p and Mir-20A-5p Suppress Postoperative Metastasis of Hepatocellular Carcinoma Via Blocking HGF/ERBB3-NF-κB Positive Feedback Loop

Bioinformatic analysis and <i>in vitro</i> validation of a five-microRNA signature as a prognostic biomarker of hepatocellular carcinoma

The Upregulation of CLGN in Hepatocellular Carcinoma is Potentially Regulated by Hsa-Mir-194-3p and Associated with Patient Progression